Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains
Journal of Medicinal Chemistry2013Vol. 56(19), pp. 7501–7515
Citations Over TimeTop 1% of 2013 papers
Olivier Mirguet, Romain Gosmini, Jérôme Toum, Catherine A. Clément, Mélanie Barnathan, Jean‐Marie Brusq, J.E. Mordaunt, Richard M. Grimes, Miriam C. Crowe, Olivier Pineau, Myriam Ajakane, Alain Daugan, Philip D. Jeffrey, Leanne Cutler, Andrea Haynes, Nicholas Smithers, Chun‐wa Chung, Paul Bamborough, Iain Uings, Antonia J. Lewis, Jason Witherington, Nigel J. Parr, Rab K. Prinjha, Edwige Nicodème
Abstract
The bromo and extra C-terminal domain (BET) family of bromodomains are involved in binding epigenetic marks on histone proteins, more specifically acetylated lysine residues. This paper describes the discovery and structure-activity relationships (SAR) of potent benzodiazepine inhibitors that disrupt the function of the BET family of bromodomains (BRD2, BRD3, and BRD4). This work has yielded a potent, selective compound I-BET762 that is now under evaluation in a phase I/II clinical trial for nuclear protein in testis (NUT) midline carcinoma and other cancers.
Related Papers
- → PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains(2013)245 cited
- → Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2020)85 cited
- → Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma(2020)47 cited
- → Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor(2018)16 cited
- → Data from Combined Targeting of the BRD4–NUT–p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734(2023)